|
 |
Late Stage Drug Development World 2009 |
|
|
1-4 December 2009
London, UK
Late stage drug development is growing at around 20% annually, exceeding the growth rate of Phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency. As a result, Health Network Communications is delighted to announce the first ever strategic forum addressing the major challenges in conducting strategic and compliant late stage studies.
The Bloomsbury Hotel, London, United Kingdom
www.healthnetworkcommunications.com/2009/LSDD
Tel: +44 (0) 207 608 7055
Fax: +44 (0) 207 608 7050
Email: jphillips@healthnetworkcommunications.com |
|
|
|
|
|
|
|
 |
Industry Events |
 |
The 2010 BIO International Convention
3-6 May 2010, Chicago, US
The 2010 BIO International Convention, 3-6th May, 2020, at McCormick Place in Chicago, Illinois, is a truly global event addressing the business of biotech.
More info >> |
|
 |
News and Press Releases |
 |
Vetter Dedicates New Facility in Suburban Chicago
Developing drugs is a slow and expensive process, especially for hard-to-treat diseases such as cancer. Biopharmaceutical companies are continuously seeking ways to accelerate development and control costs. With the dedication today of its new 24,000-square-foot facility at the Illinois Science + Technology Park in Skokie, Vetter may enable life sciences firms to streamline their early development process and cut time to market.
More info >> |
|
|
